Market Overview

The Technical Take: Dynavax Wrecked After CRL Letter

Related DVAX
Jim Cramer Weighs In On Barrick Gold, Childrens Place And More
The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines
Playing The Expectations Game In Biotech (Seeking Alpha)

Dynavax Technologies Corporation (NASDAQ: DVAX) shares are trading lower by $7.40 (64 percent) at $4.20 in Monday's session. Investors are exiting the issue after getting a CRL from the FDA for its marketing application for Heplisav-B.

After swooning to the $3 area in pre-market trading, shorts and new longs came in buying off the open. As a result, it bottomed a nickel off its opening print of $3.25 at $3.20 and began to rally.
That marks the lowest level for the issue since December 16, 2008, when it bottomed at $2.46.

The ensuing rebound took the issue to $4.70, but it has backed off that high.

Today's price action is taking place on much higher than average volume. With about five hours remaining in the session, 19.2 million shares have traded compared to its 20-day average of 1.4 million.

Posted-In: Technicals Intraday Update Movers Trading Ideas


Related Articles (DVAX)

View Comments and Join the Discussion!